|Day's Range||0.006 - 0.006|
|52 Week Range||0.005 - 0.010|
|PE Ratio (TTM)||-3.00|
|Earnings Date||Aug 30, 2016 - Sep 3, 2016|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
This Big Brother is more sclerotic than sinister -- and needs our help.
The data analytics firm employed by President Trump's campaign team has hit back at allegations that it may have breached U.K. data protection rights.
DENVER, July 13, 2016 /PRNewswire/ -- Analytica (ASX: ALT) today announced that the U.S. Food and Drug Administration (FDA) has approved the PeriCoach® at-home pelvic floor trainer device and smartphone app as an over-the-counter (OTC) treatment for treatment of mild, moderate and stress urinary incontinence (UI) and urge incontinence. A strong pelvic floor is also associated with improved sexual function and satisfaction.